About WuXi AppTec
WuXi AppTec is a publicly listed company based in Shanghai (China) founded in 2000. Provider of CRO and CDMO services. WuXi AppTec has raised $40 million across 5 funding rounds from investors including General Atlantic, Warburg Pincus and Eight Roads Ventures. The company has 1,681 employees. WuXi AppTec has completed 10 acquisitions, including Abgent, Ambrx and Crelux. Its website wuxiapptec.com draws about 108 thousand monthly visits. Its focus areas include Biopharma Outsourcing and Diversified.
Company details
WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device RD process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPKADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of 5.84B and a net profit of 1.31B.
- Headquarters Shanghai, China
- Employees 1,681
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website wuxiapptec.com
- Social LinkedIn X
- Annual Revenue$8.27 M (USD)-3as on Dec 31, 2023
- Net Profit-$9.82 M (USD)48as on Dec 31, 2023
- Total Equity Funding$40M (USD)
in 5 rounds
- Latest Funding Round$15.88M (USD), Post-IPO
Apr 2021
- InvestorsGeneral Atlantic
& 4 more
- Employee Count1,681
- Investments & AcquisitionsAbgent
& 9 more
Funding Insights of WuXi AppTec
WuXi AppTec has successfully raised a total of $40M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15.88 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 5
- Last Round Post-IPO — $15.88M
- First Round $40M
(Feb 2007)
- Investors Count 5
All 5 funding rounds of WuXi AppTec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $15.88M | Post-IPO | – | – | |
| Aug 2020 | $950.63M | Post-IPO | – | – | – |
| Mar 2016 | $1.5B | Debt – Conventional | – | – | |
| Jul 2008 | Series C | – | – | ||
| Feb 2007 | $40M | Series B | – | – |
5 investors in total: 5 institutional.
Investors in WuXi AppTec
WuXi AppTec has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include General Atlantic, Warburg Pincus and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
| 2019 | 120capm.com | Darien, United States | ||
Commercial bank | 1987 | bank.pingan.com | Shenzhen, China |
Investor details for WuXi AppTec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of WuXi AppTec
114 people are tracked at WuXi AppTec (75 in leadership, 39 in team); the tracked headcount is 1,681.
| Name | Role | Group |
|---|---|---|
Ge Li | Chairman & CEO | Leadership |
Feng Zhang | SVP, Head of STA API Manufacturing | Leadership |
Kevin Denny | Executive Director Technical Operations (toxicology) | Leadership |
Jinling Chen | SVP, Head of STA DP Business | Leadership |
Jinpeng Li | Director, Pre-clinical Immunotoxicology | Leadership |
Minzhang Chen | Co-CEO | Leadership |
Steve Yang | Co-CEO | Leadership |
Edward Hu | Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU | Leadership |
Howard Wu | SVP, General Counsel, Global Head of Human Resources & Deputy Director of WuXi AppTec Management Institute | Leadership |
Zhaohui Zhang | China Chief Operating Officer, Executive Vice President | Leadership |
Youchu Wang | SVP, Head of STA API Early Phase Development | Leadership |
Edison Jiang | Director, Head Of Talent Acquisition HR Coe | Leadership |
Karen Dimsey | Sr. Director, Head Of US & EU Talent Acquisition | Leadership |
Sophie Rose | Business Development Director | Leadership |
Sharlene Tracanna | Associate Director, Human Resources-california/austin,tx | Leadership |
Denise Witter | Senior Director, HRIS And Operations | Leadership |
Weixia Zhang | Director For Hits Microfluidics Platform | Leadership |
Kev Hannity McIpd | Senior HR Business Partner - Europe | Leadership |
David Chang | President & CTO of WuXi ATU | Leadership |
Jessie Zhu | Learning And Development, Talent, OD Director | Leadership |
94 more people are available in the full profile.
Complete people profiles for WuXi AppTec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by WuXi AppTec
WuXi AppTec has strategically engaged in corporate development activities, having acquired 10 companies. Notable acquisitions include Abgent, Ambrx and Crelux.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of a platform for mammalian cell engineering | oxgene.com | Oxford, United Kingdom | 2011 | Mar 2021 | •••• | |
Drug quality control solutions are provided for pharmaceuticals. | mstonepharma.com | Nanjing, China | 2018 | Sep 2020 | •••• | |
Integrated silicon photonics products are developed for optical communication applications. | pharmapace.com | San Diego, United States | 2013 | May 2019 | •••• | |
Supplier of screen printing supplies and equipment | researchpointglobal.com | Austin, United States | 1999 | Oct 2017 | •••• | |
Preclinical CRO services in gene manipulation-based target validation are provided. | hdbiosciences.com | Shanghai, China | 2002 | Jan 2017 | •••• | |
X-ray crystallography and fragment-based drug discovery services are provided. | crelux.com | Planegg, Germany | 2005 | Apr 2016 | •••• | |
Antibody-drug conjugates are developed for cancers and metabolic disorders. | ambrx.com | San Diego, United States | 2003 | May 2015 | •••• | |
Genomics platform for clinical insights and rapid diagnoses is provided. | nextcode.com | Cambridge, United States | 2013 | Jan 2015 | $65M | |
Offers bioanalytical services | xbl.com | Plainsboro, United States | 1987 | Oct 2014 | •••• | |
Primary antibodies are developed for research and drug discovery. | abgent.com | San Diego, United States | 2001 | Oct 2011 | •••• |
Complete acquisition details for WuXi AppTec
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of WuXi AppTec
14 dated milestones of WuXi AppTec across 21 years, from founding to its latest funding, stage changes and deals.
- Founded WuXi AppTec is founded.
- Funding First funding round of $40.0M.
- Acquisition Acquires Abgent.
- Acquisition Acquires XenoBiotic Laboratories.
- Acquisition Acquires NextCode Health.
- Acquisition Acquires Ambrx.
- Acquisition Acquires Crelux.
- Acquisition Acquires HD Biosciences.
- Acquisition Acquires ResearchPoint Global.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Pharmapace.
- Acquisition Acquires Mingjie Pharmaceutical.
- Acquisition Acquires OXGENE.
- Funding Latest funding round, Post-IPO, of $15.9M.
Web traffic of WuXi AppTec
The website of WuXi AppTec (wuxiapptec.com) receives about 107.6K visits a month and ranks #296,852 among all websites worldwide, #240 in Biotechnology and Pharmaceuticals.
- Monthly visits107.6K
▲ 3.4% vs previous month
- Unique visitors43.2K
per month
- Global rank#296,852
among all websites
- Category rank#240
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit3.8
- Average visit2 min 56 sec
- DevicesDesktop 59% · Mobile 41%
Websites whose visitors overlap most with WuXi AppTec. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bioduro.com | 100% | 6.9K | #3,126,038 | View details | |
| yangzijiang.com | 100% | #559,311 | View details | ||
| cellcarta.com | 96% | 25.5K | #1,270,300 | View details | |
| zeta.com | 96% | #643,592 | View details | ||
| wuxibiologics.com | 95% | 172.3K | #175,288 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for WuXi AppTec
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Wuxi Apptec
Complete news archive for WuXi AppTec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about WuXi AppTec
WuXi AppTec was founded in 2000 and raised its 1st funding round 7 years after it was founded.
WuXi AppTec is headquartered in Shanghai, China.
WuXi AppTec is a funded company, having raised a total of $40M across 5 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Feb 2007.
WuXi AppTec has 1,681 employees.
Annual revenue of WuXi AppTec is $8.27M as on Dec 31, 2023.
WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device RD process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPKADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of 5.84B and a net profit of 1.31B.
WuXi AppTec has 5 investors. Key investors include General Atlantic, Warburg Pincus, Eight Roads Ventures, Ping An Bank, and 120 Capital Management.
The website of WuXi AppTec receives about 108 thousand visits a month and ranks #296,852 among all websites worldwide.